1320-1321 / 2437
Take home messages
• Cure is probably restricted to younger patients
• Standard of care is only poorly defined
=> further trials are urgently needed
• HD-MTX as the therapeutic backbone / rituximab increasingly used
• WBRT should be avoided in the first-line setting
• Open questions:
• Role for new drugs, e.g. immune checkpoint inhibitors,
ibrutinib…?
• Optimal treatment for elderly/frail patients?